PET Scans in Patients With Locally Advanced Breast Cancer
NCT00109785 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8
Last updated 2015-12-24
Summary
RATIONALE: Imaging procedures such as PET scans may improve the ability to monitor the effectiveness of chemotherapy for locally advanced breast cancer.
PURPOSE: This clinical trial is studying how well PET scans work in patients with locally advanced breast cancer who will undergo chemotherapy.
Conditions
Interventions
- PROCEDURE
-
positron emission tomography
- RADIATION
-
fludeoxyglucose F 18
- RADIATION
-
iodine I 124 iododeoxyuridine
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
Memorial Sloan Kettering Cancer Center
lead OTHER
Principal Investigators
-
Teresa Ann Gilewski, MD · Memorial Sloan Kettering Cancer Center
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 120 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1997-03-31
- Primary Completion
- 2008-12-31
- Completion
- 2008-12-31
Countries
- United States
Study Locations
More Related Trials
-
PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer
NCT01712815 ·Status: TERMINATED ·Phase: NA
-
Phase II Study of Fluorine-18 3'-Deoxy-3'-Fluorothymidine (F-18-FLT) in Invasive Breast Cancer
NCT00572728 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer
NCT06145399 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer
NCT06557148 ·Status: RECRUITING
-
FDG PET-CT in Advanced Breast Cancer
NCT07173868 ·Status: RECRUITING
-
PET Scans in Assessing Response To Treatment in Patients Receiving Hormone Therapy or Trastuzumab for Breast Cancer
NCT00362973 ·Status: COMPLETED
-
PET/CT Evaluation of Treatment Response in Breast Cancer
NCT01222416 ·Status: TERMINATED ·Phase: NA
-
PET and MRI in the Follow-up of Neoadjuvant Chemotherapy of Breast Cancer
NCT00236275 ·Status: COMPLETED ·Phase: PHASE3
-
[18F] F-GLN by PET/CT in Breast Cancer
NCT03863457 ·Status: RECRUITING ·Phase: PHASE1
-
Anti-1-amino-3-[18F]Fluorocyclobutyl-1-carboxylic Acid (Anti-[18F](FACBC)Positron Emission Tomography (PET-CT) of the Breast
NCT01659645 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy
NCT02398773 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Positron Emission Tomography Imaging Using Copper Cu 64 TP3805 in Patients With Breast Cancer
NCT02810873 ·Status: TERMINATED ·Phase: NA
-
Fluoroestradiol PET Imaging in Predicting Response to Hormone Therapy of Breast Cancer
NCT01627704 ·Status: COMPLETED ·Phase: NA
-
[18F]FES PET/CT in Endocrine Refractory Breast Cancer
NCT02409316 ·Status: COMPLETED ·Phase: PHASE2
-
Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors
NCT00588276 ·Status: COMPLETED ·Phase: PHASE1
-
18F-FLT-PET Imaging of the Brain in Patients With Metastatic Breast Cancer to the Brain Treated With Whole Brain Radiation Therapy With or Without Sorafenib: Comparison With MR Imaging of the Brain
NCT01621906 ·Status: COMPLETED ·Phase: NA
-
[18F]ISO-1 Positron Emission Tomography (PET/CT) in Primary Breast Cancer
NCT02284919 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
PET and/or MRI Scans in Assessing Tumor Response in Patients Receiving Antiangiogenesis Therapy
NCT00019565 ·Status: COMPLETED ·Phase: PHASE1
-
[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma
NCT04252859 ·Status: TERMINATED ·Phase: PHASE2
-
18F-fluoroestradiol (FES) PET/CT for Breast Cancer
NCT04883814 ·Status: UNKNOWN ·Phase: PHASE2
-
F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy
NCT02149173 ·Status: TERMINATED ·Phase: NA
-
Positron Emission Mammography With Fluorothymidine (FLT) to Evaluate Treatment Response to Chemotherapy in Breast Cancer
NCT00934401 ·Status: WITHDRAWN
-
Early Assessment of the Response to Neo-adjuvant Chemotherapy in Breast Cancer Patients With FDG-PET
NCT00904410 ·Status: COMPLETED ·Phase: PHASE4
-
Monitor Response to Treatment in Neuroblastoma Using 3&Apos;-Deoxy-3&Apos;-Fluorothymidine- Positron Emission Tomography (FLT-PET)
NCT01308905 ·Status: UNKNOWN ·Phase: NA
-
FDG PET/CT in Breast Cancer Bone Mets
NCT01996046 ·Status: ACTIVE_NOT_RECRUITING